Polyneuropathy developing after infliximab therapy in a patient with recalcitrant pyoderma gangrenosum.
The use of tumor necrosis factor-alpha (TNF-α) inhibitors has increased tremendously during the recent years. Neurological side effects associated with TNF-α inhibitors are rarely encountered, but these side effects may result in serious clinical problems. Treatment with TNF-α inhibitors is associat...
| Published in: | Turkish Archives of Dermatology & Venerology / Turkderm Vol. 53; no. 1; pp. 24 - 28 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | case study pictorial Journal Article |
| Published: |
Galenos Yayinevi Tic. LTD. STI
2019
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135805901&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135805901 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1019214X L94P jtl: Turkish Archives of Dermatology & Venerology / Turkderm issn: 1019214X maglogo: N pubinfo: dt: 2019 vid: 53 iid: 1 pid: 28155 pub: Galenos Yayinevi Tic. LTD. STI artinfo: ui: 135805901 135805901 135805901 10.4274/turkderm.galenos.2018.70437 135805901 ppf: 24 ppct: 4 formats: tig: atl: Polyneuropathy developing after infliximab therapy in a patient with recalcitrant pyoderma gangrenosum. aug: au: Singer, Ralfi Örken, Cihat Güngör, Şule Çopur, Mehmet Kızıltaç, Utkan Kızıltaç, Kübra Göncü, Emek Kocatürk Erhan, Selma Şengiz affil: İstanbul Okmeydanı Training and Research Hospital, Clinic of Dermatology and Venereology, İstanbul, Turkey sug: subj: Tumor Necrosis Factor Antagonists and Inhibitors Tumor Necrosis Factor Adverse Effects Demyelinating Diseases Risk Factors Infliximab Polyneuropathies Risk Factors Female Adult Leg Ulcer Biopsy Pyoderma Gangrenosum Diagnosis Triamcinolone Tacrolimus Hyperbaric Oxygenation Treatment Outcomes Adult: 19-44 years Female ab: The use of tumor necrosis factor-alpha (TNF-α) inhibitors has increased tremendously during the recent years. Neurological side effects associated with TNF-α inhibitors are rarely encountered, but these side effects may result in serious clinical problems. Treatment with TNF-α inhibitors is associated with demyelinating syndromes which can affect both the central and peripheral nervous systems. Short-term follow-up indicates relatively good outcomes, sometimes after just treatment discontinuation, although corticosteroids or intravenous immunoglobulin may be necessary to reverse the conditions in some cases. Here, we present a case of motor neuropathy developing after treatment with infliximab in a patient with recalcitrant pyoderma gangrenosum. Tümör nekroz faktörü-alfa (TNF-α) inhibitörlerinin birçok romatizmal ve otoimmün hastalığın tedavisinde kullanımları son yıllarda artmıştır. TNF-α inhibitörlerine bağlı nörolojik yan etkiler nadir görülmelerine karşın oldukça ciddi komplikasyonlar oluşturabilirler. TNF-α inhibitörleri hem santral hem de periferik sinir sistemine ilişkin demiyelinizan tablolara yol açabilir. Klinik tablo, biyolojik ajan tedavisinin kesilmesi ile düzelebildiği gibi, bazı olgularda sistemik steroid veya intravenöz immünoglobülin tedavisine gereksinim duyulabilir. Burada, standart tedaviye dirençli piyoderma gangrenosum nedeniyle infliksimab tedavisi başlanmasından sonra motor nöropati gelişen bir olgu sunulmaktadır. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|